Oncology company Selvita (WSE:SLV) stated on Tuesday that it recorded a net loss (EBITDA excluding IFRS16 impact) of USD2.2m for the first quarter ended 31 March 2019.
This is a decline in earnings when compared with net loss of USD0.6m for the comparable quarter ended 31 March 2018.
Revenues attributable to non-dilutive grant sources of USD1.9m were generated for the quarter ended 31 March 2019, up over grant revenues of USD1.1m for the quarter ended 31 March 2018.
Research and development expenses of USD4.9m were recorded for the quarter ended 31 March 2019, a rise of USD2.2m from R&D of USD2.7m for the same period ended 31 March 2018, which was attributable to increase in costs of SEL120 development, as well as intensified research and development activities.
Additionally, the company's Investigational New Drug (IND) application to launch a Phase 1 study of selective CDK8 inhibitor SEL120 was approved by US Food and Drug Administration (FDA); Dosing of first patient in Phase 1 study of SEL120 is planned in the Q3 2019; and the split of oncology therapeutics and research services divisions into independent public companies is expected to be completed in the Q4 2019.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial